152 related articles for article (PubMed ID: 18686047)
1. Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2009; 26(2):124-30. PubMed ID: 18686047
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2007; 24(4):372-8. PubMed ID: 17917084
[TBL] [Abstract][Full Text] [Related]
3. Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2008; 25(2):182-6. PubMed ID: 17972023
[TBL] [Abstract][Full Text] [Related]
4. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2007; 24(2):189-96. PubMed ID: 17848743
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.
Rubenstein M; Tsui P; Guinan P
Methods Find Exp Clin Pharmacol; 2006 Oct; 28(8):515-8. PubMed ID: 17136230
[TBL] [Abstract][Full Text] [Related]
6. Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2010 Sep; 27(3):592-9. PubMed ID: 19533419
[TBL] [Abstract][Full Text] [Related]
7. Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2012 Jun; 29(2):835-41. PubMed ID: 21573974
[TBL] [Abstract][Full Text] [Related]
8. Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2010 Dec; 27(4):1212-8. PubMed ID: 19937163
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells.
Rubenstein M; Guinan P
In Vivo; 2010; 24(4):489-93. PubMed ID: 20668314
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivation.
Rubenstein M; Chou P; Mirochnik Y; Guinan P
Med Oncol; 1997 Mar; 14(1):23-9. PubMed ID: 9232607
[TBL] [Abstract][Full Text] [Related]
11. Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines.
Rubenstein M; Slobodskoy L; Mirochnik Y; Guinan P
Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):649-52. PubMed ID: 12616956
[TBL] [Abstract][Full Text] [Related]
12. Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expression.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2011; 25(5):725-32. PubMed ID: 21753125
[TBL] [Abstract][Full Text] [Related]
13. Bispecific oligonucleotides may induce interferon expression in LNCaP cells enhancing surface antigen expression: effect of intrastrand base pair complementarity.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2011; 25(1):61-7. PubMed ID: 21282736
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer.
Rubenstein M; Anderson KM; Tsui P; Guinan P
Med Hypotheses; 2006; 67(6):1375-80. PubMed ID: 16870352
[TBL] [Abstract][Full Text] [Related]
15. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.
Rubenstein M; Tsui P; Guinan P
Med Hypotheses; 2005; 65(5):905-7. PubMed ID: 16023790
[TBL] [Abstract][Full Text] [Related]
16. Bax expression remains unchanged following antisense treatment directed against BCL-2.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2011 Sep; 28(3):852-8. PubMed ID: 20422317
[TBL] [Abstract][Full Text] [Related]
17. Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides.
Rubenstein M; Mirochnik Y; Chou P; Guinan P
Methods Find Exp Clin Pharmacol; 1998 Dec; 20(10):825-31. PubMed ID: 10091218
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol.
Rubenstein M; Slobodskoy L; Mirochnik Y; Guinan P
Med Oncol; 2003; 20(1):29-35. PubMed ID: 12665682
[TBL] [Abstract][Full Text] [Related]
19. Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor.
Rubenstein M; Glick R; Lichtor T; Mirochnik Y; Chou P; Guinan P
Med Oncol; 2001; 18(2):121-30. PubMed ID: 11778757
[TBL] [Abstract][Full Text] [Related]
20. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
